Table 2.
Results from covariate-adjusted, asymmetric FE regressions analyzing the longitudinal association between transitions in GAD, MDE and change in QoL over time
| Independent variables | Outcomes (change in CASP-12 domains) | |||
|---|---|---|---|---|
| Self-realization/pleasure | Control/autonomy | |||
| b (SE) | Wald test of coefficients | b (SE) | Wald test of coefficients | |
| Incident GAD (ref: no incident GAD) | – 0.18 (0.28) | F (1, 3937) = 1.23, p = 0.267 | – 0.34 (0.40) | F (1, 3644) = 0.20, p = 0.653 |
| Remission of GAD (ref: no remission of GAD) | 0.61* (0.26) | 0.58 (0.36) | ||
| Incident MDE (ref: no incident MDE) | – 0.08 (0.21) | F (1, 3937) = 3.22, p = 0.073 | – 0.74* (0.30) | F (1, 3644) = 0.33, p = 0.567 |
| Remission of MDE (ref: no remission of MDE) | 0.61** (0.20) | 0.50 (0.29) | ||
| Covariatesa | ✔ | ✔ | ||
| Number of observations | 3955 | 3662 | ||
| R2 | 0.012 | 0.009 | ||
**p < 0.01, *p < 0.05
CASP-12 12-item version of the CASP-19 quality of life scale, GAD Generalized anxiety disorder, MDE Major depressive episode
Results obtained from asymmetric linear FE regressions (displayed as regression coefficients with standard errors in parentheses) and post-estimation Wald tests of the coefficients (b+ = − b−). Listwise deletion was used to handle missing values
aAll models were additionally adjusted for age group, retirement status, marital status, presence of chronic conditions, number of difficulties in activities of daily living, cognitive function, and receipt of antidepressant medication (data for covariates shown in Online Appendix)